Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Cancer Genome Atlas Identifies Distinct Subtypes of Deadly Brain Cancer

Published: Thursday, January 21, 2010
Last Updated: Thursday, January 21, 2010
Bookmark and Share
According to study the most common form of malignant brain cancer in adults appears to be four distinct molecular subtypes.

The most common form of malignant brain cancer in adults, glioblastoma multiforme (GBM), is not a single disease but appears to be four distinct molecular subtypes, according to a study by The Cancer Genome Atlas (TCGA) Research Network.

The researchers of this study also found that response to aggressive chemotherapy and radiation differed by subtype. Patients with one subtype treated with this strategy appeared to succumb to their disease at a rate approximately 50 percent slower than patients treated with less aggressive therapy. This effect was seen to a lesser degree in two of the subtypes and not at all in the fourth subtype.

Although the findings do not affect current clinical practice, the researchers said the results may lead to more personalized approaches to treating groups of GBM patients based on their genomic alterations.

The study, published Jan. 19, 2010 in Cancer Cell, provides a solid framework for investigation of targeted therapies that may improve the near uniformly fatal prognosis of this cancer. The research team for TCGA is a collaborative effort funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both parts of the National Institutes of Health.

"TCGA is mobilizing the entire cancer community to find new strategies in detecting and treating cancer faster," said NIH Director Francis Collins, M.D., Ph.D. "These findings are just a hint of what we expect to result from the comprehensive data generated by TCGA over the next few years."

GBM is a very fast-growing type of tumor. In recent years, 3 of every 100,000 Americans have been diagnosed with GBM, representing the highest incidence rate among malignant brain tumors. Most patients with GBM die of the disease within approximately 14 months of diagnosis.

"These new findings offer critical insights into stratifying patients based on the unique molecular characteristics of their disease," said John E. Niederhuber, M.D., NCI director. "As we learn more and more about the genetic underpinnings of cancer, we hope to achieve a similar level of molecular understanding for all cancers and eventually to generate recipes of highly targeted therapies uniquely suited to the individual patient."

The TCGA researchers expanded on previous studies, which had established gene expression profiling as a means to identify distinct subgroups of GBM.

"We discovered a bundle of events that unequivocally occur almost exclusively within a subtype," said lead author D. Neil Hayes, M.D., University of North Carolina at Chapel Hill. "These are critical events in the history of the tumor's development and spread, and evidence is increasing that they may relate to the initial formation of the tumors."

TCGA researchers reported that the nature of these events indicate that the underlying pathology of each subtype may begin from different types of cells. This may provide a better understanding of which cell types undergo changes that ultimately drive initial cancer formation.

This finding has potential clinical significance since determining the types of cells that form GBM is critical for establishing effective treatment regimens. Because the response to aggressive chemotherapy and radiation differed by subtype, some classes of drugs would be expected to work for some tumor subtypes and not others.

"The ability to differentiate GBM tumors based on their altered genetic code lays the groundwork for more effective treatment strategies to combat this deadly cancer," said Eric D. Green, M.D., Ph.D., NHGRI director. "These findings demonstrate the power of using a cancer's genome to unravel the molecular changes that occur in the various cancer types targeted by TCGA. I'm optimistic that this type of knowledge will someday lead to improved personalized therapies and care for cancer patients."

The new findings build on TCGA's detailed view of GBM genomic changes reported in Nature in October 2008. TCGA, launched in 2006, is a comprehensive and coordinated effort to accelerate understanding of the molecular basis of cancer through the application of genome analysis technologies, including large-scale genome sequencing.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Near-Atomic Resolution of Protein Structure Holds Promise for Drug Discovery
A new study shows that it is possible to use an imaging technique called cryo-electron microscopy to view the architecture of a metabolic enzyme bound to a drug that blocks its activity.
Friday, May 08, 2015
National Cancer Institute Awards Two Lung Cancer CTC Development Contracts to Cynvenio Biosystems, Inc.
Company also announces additional equity investment of $2.0 million.
Tuesday, February 07, 2012
2011 Biospecimen Research Network (BRN) Symposium
The National Cancer Institute's (NCI) Biospecimen Research Network Symposium, "Advancing Cancer Research Through Biospecimen Science," will be held March 28-29, 2011, at the Bethesda North Marriott Hotel & Conference Center in Bethesda, MD
Friday, January 07, 2011
NCI Announces Plans to Reinvigorate Clinical Trials
The National Cancer Institute (NCI) has announced major changes to be made in the long-established Clinical Trials Cooperative Group Program that conducts many of the nationwide trials of new cancer therapies.
Friday, December 24, 2010
National Cancer Institute Awards Nearly $4M to University of new Mexico Cancer Center
The awards support cancer nanotechnology partnership with Sandia Labs.
Wednesday, November 10, 2010
Scientists Identify Markers on Human Breast Cancer Cells Linked to Development of a Form of Breast Cancer
The scientists named these human cells with tumor-forming ability in mice, xenograft-initiating cells, or XIC.
Friday, May 21, 2010
Expression of Proteins Linked to Poor Outcome in Women with Ovarian Cancer
The study led by NCI scientists may provide targets for the development of novel therapies for ovarian cancer.
Wednesday, April 21, 2010
Antibodies Against Abnormal Glycoproteins Identified as Possible Biomarkers for Cancer Detection
Scientists have found that cancer patients produce antibodies that target abnormal glycoproteins made by their tumors.
Thursday, February 04, 2010
Diet May Protect Against Gene Changes in Smokers
A new study finds that leafy green vegetables, folate, and multivitamins could serve as protective factors against lung cancer in smokers.
Thursday, January 14, 2010
Gene Mutations Reveal Potential new Targets for Treating a Type of Non-Hodgkin's Lymphoma
Findings provide insight into a mechanism that cancer cells may use to survive.
Tuesday, January 12, 2010
Gene Mutations Reveal Potential new Targets for Treating a Type of Non-Hodgkin's Lymphoma
Findings provide insight into a mechanism that cancer cells may use to survive.
Friday, January 08, 2010
Drug for Multiple Myeloma Demonstrated to Extend Disease-Free Survival
Patients receiving lenalidomide following a blood stem cell transplant had their cancer kept in check longer than placebo receiving patients.
Thursday, December 24, 2009
Gene's Position in the Nucleus Can be Used to Distinguish Cancerous from Normal Breast Tissue
Researchers have identified several genes whose spatial position inside the cell nucleus is altered in invasive breast cancer.
Wednesday, December 09, 2009
Centralized Review Process Markedly Expedites Approval of Cancer Clinical Trials
CIRB for cancer clinical trials, which was created by the National Cancer Institute, expedites the time from concept to completion of crucial investigational research.
Thursday, November 05, 2009
Duplicated Gene May Explain Rare Cancer in Some Families
NCI researchers have now identified a genetic change that may lead to chordoma, a type of bone cancer, in four of the families.
Monday, October 26, 2009
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!